Title of the cohort

Study – Whitehall II

Acronym for cohort

WII / Health and Stress Study

Name of Principal Investigator
Title In transition: Prof Sir and Prof
First name Michael and Mika
Last name Marmot and Kivimaki
Address of institution where award is held
Institution UCL
Street Address 1-19 Torrington Place
City London
Postcode WC1E 6BT
Country

United Kingdom

Website

http://www.ucl.ac.uk/whitehallII/

Contact email

e.dahm-vicker@ucl.ac.uk

Funding source

MRC, BHF, NHLBI, NIA

1. The cohort includes, or expects to include, incidence of the following conditions
  • Neurodegenerative disease in general
When studies on the above condition(s) are expected to become possible

2016 – 2025

2a. Stated aim of the cohort

Extensive data on clinical and subclinical morbidity and mortality as well as repeat measures of biological, behavioural, socioeconomic and psychosocial factors from midlife to old age (10 data waves over 20 years of follow-up).

2b. Features distinguishing this cohort from other population cohorts

Extensive data on clinical and subclinical morbidity and mortality as well as repeat measures of biological, behavioural, socioeconomic and psychosocial factors from midlife to old age (10 data waves over 20 years of follow-up).

3a. i) Number of publications that involve use of cohort to date

Biological measures, such as BP, Serum Cholesterol, Serum Triglycerides, HDL/LDL, Glucose (fasting & postload), Insulin (fasting & postload), HbA1C, CRP, IL-6, genetic variants.Measures for cognitive physical function, such as timed walk, lung function and memory test. Behavioural factors such physical activity, smoking and alcohol consumption. Socioeconomic and psychosocial factors.

3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)

PIs Marmot M, Kivimaki M, Singh-Manoux A., Brunner EJ. UCL, London UK.

Marmot MG, Smith GD, Standfeld SA et al. Health inequalities among British civil-servants – the Whitehall II study 1991;337:1387-93.

Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M,* Witte DR.* Trajectories of glycemia, insulin sensitivity and insulin secretion preceding the diagnosis of type 2 diabetes: the Whitehall II study. Lancet 2009;373:2215-21. (*contributed equally)

Singh-Manoux A, Marmot MG, Glymour M, Sabia S, Kivimaki M, Dugravot A. does cognitive reserve shape cognitive decline? Ann Neurol in press.

3b. Publication list/link to where data or publications are accessible (if available)

http://www.ucl.ac.uk/whitehallII/research;
http://www.ucl.ac.uk/whitehallII/publications

3c. Information (i.e. research findings) expected to be gained from the population cohort
4a. Study criteria: age range of participants at recruitment
Age in years from: 35-55
To (‘until death’ if applicable): until death
4b. Study criteria: inclusion criteria

All male and female civil servants working in 20 London-based departments.

4c. Study criteria: exclusion criteria

Please see Q4b.

5. Size of the cohort (i.e. number of participants enrolled)

10,001 – 15,000 participants

6a. Measures used to characterise participants

Biological measures, such as BP, Serum Cholesterol, Serum Triglycerides, HDL/LDL, Glucose (fasting & postload), Insulin (fasting & postload), HbA1C, CRP, IL-6, genetic variants.Measures for cognitive physical function, such as timed walk, lung function and memory test. Behavioural factors such physical activity, smoking and alcohol consumption. Socioeconomic and psychosocial factors.

6b. Additional measures for participants with a clinical disorder
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

No

7. Study design

Prospective cohort

8. Cases matched by
  • Other health assessment (specify) / N/A
  • please see Q4b
9a. Does the study include a specialised subset of control participants

No

9b. If yes, description of specialised subset of control participants

No specialised subsets of control participants.

10a. i) Data collection start date

27-08-1985

10a. ii) Data collection end date
10a iii) Data collection for this study is
  • Data collection ongoing
  • Data analysis ongoing
10b. Plans to continue the cohort study beyond the current projected end date
  • Yes – intend to apply for funding
11. Data collected
  • Only through the study
  • Through links to medical records
12. System in place to enable re-contact with patients for future studies

Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

13a. Format and availability of data stored in a database
Language used:
13b. Format and availability of data held as individual records
Yes/No % available
Data held as individual records  Y  100
Data is web-based N
Data held on computer based records  Y  80
Data held on cards  Y  20
Other (specify)

 

Language used:

English

14a. Are data available to other groups

Yes

14b. Access policy/mechanisms for access if data are available to other groups
  • Apply to PI or co-ordinator at resource
  • Access independent of collaboration with PI
  • Access Committee mechanism
  • Local/ regional access
  • National access
  • International access
  • Resource has own ethics approval so usually no need for separate external ethics approval
15. Data sharing policy specified as a condition of use

Data made publicly available after a specified time point

16a. Are tissues/samples/DNA available to other groups

No

16b. i) Description of available tissues/samples/DNA
16b. ii) Form available tissues/samples/DNA are supplied in
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data
17. Is information on biological characteristics available to other groups

Yes, for all the cohort

Types: Population Cohorts
Member States: United Kingdom
Diseases: Neurodegenerative disease in general
Years: N/A
Database Categories: N/A
Database Tags: N/A

Export as PDF